Phathom Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
10analysts covering
FY Revenue (est.)
$316.6Mnext fiscal year
FY EPS (est.)
-$0.03next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
VOQUEZNA Net Revenues Quarterly58.3MTarget: $320 million to $345 million for FY 2026
Total VOQUEZNA Prescriptions Filled (Cumulative) Quarterly1.4MTarget: Continued growth toward $1 billion annual revenue potential
Quarterly VOQUEZNA Prescriptions Filled Quarterly268KTarget: Sequential volume growth following sales force realignment
Insurance Coverage Rate for Prescriptions Quarterly63.0%Target: Expansion of commercial and Medicare coverage
Watch Items
- Operating Profitability MilestoneTrigger: Excluding stock-based compensation, achieving positive operating incomeAction: Monitor Q3 2026 financial results to confirm execution of the profitability timeline.
- Phase 2 pHalcon-EoE-201 Topline ResultsTrigger: Topline data readout for VOQUEZNA in eosinophilic esophagitisAction: Track clinical trial progress in late Q4 2026 or early Q1 2027.
- Gross-to-Net (GTN) Discount RateTrigger: GTN discount rate exceeding the guided 55% to 59% rangeAction: Evaluate pricing pressure and payer contract terms if GTN discounts rise above 59%.
Research as of 19 Jun 2026